Objectives In recent years, discussions on the importance and scope of therapeutic value of
new medicines have intensified, stimulated by the increase of prices and number of …

Background Cancer medicines usually have uncertain efficacy and safety profiles when they
are first approved by medicines regulators because this evidence usually emerges post …

Background Cancer rates and expenditures are increasing, resulting in debates on the exact
value of this care. Perspectives on what exactly constitutes worthwhile values differ. This …

Introduction Even using well-established technology assessment processes, the basis of the
decisions on drug price and reimbursement are sometimes perceived as poorly informed …

Background Neoadjuvant chemoradiotherapy for oesophageal cancer significantly improves
overall survival but is associated with severe post-operative complications. Proton beam …

Purpose Despite the importance of acknowledging patient preferences in treatment decision-
making, little is known about the treatment preferences and the factors underlying those …

Background Clinical indications for ibrutinib reimbursement in Australia should consider the
inclusion of patients with chronic lymphocytic leukemia (CLL) harboring prognostically …

Objectives To inform the stepwise transformation to value-based healthcare in Saudi Arabia,
we assess physicians' priorities for measuring general patient outcomes. This is done as an …

The incorporation of therapeutic innovations must fulfil a triple objective in a balanced way:
to ensure patients' access to effective innovative solutions, to guarantee the economic …

In the ever-evolving landscape of healthcare, value-based healthcare (VBHC) has emerged
as a transformation strategy that shifts the focus from increasing volume to improving the …